CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ceryvyn Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ceryvyn Therapeutics Ltd
C/- Prime Company Compliance
Level 9, 505 Little Collins Street
Phone: +61 398260399p:+61 398260399 MELBOURNE, VIC  3000  Australia Ticker: CYVCYV
Business Summary
Ceryvyn Therapeutics Limited, formerly Opthea Limited, is an Australia-based clinical-stage biopharmaceutical company. The Company is focusing on developing therapies by translating advances in human biology into transformative medicines for patients with serious diseases. It focuses on identifying biological mechanisms that drive disease and developing targeted therapies capable of addressing unmet medical needs. Its focus is lymphangioleiomyomatosis (LAM), a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. The Company's lead development program, CYV-101, is a fusion protein designed to selectively bind and neutralize VEGF-C and VEGF-D, key signaling proteins involved in pathological lymphangiogenesis. It targets a fundamental biological pathway to drive disease progression, CYV-101 offers a differentiated therapeutic approach for patients with LAM.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20256/30/2025YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Jeremy M.Levin 72 10/12/2020 10/12/2020
Founder, Chief Innovation Office MeganBaldwin 49 11/15/2024 1/1/2009
Chief Financial Officer, Joint Company Secretary HamishGeorge 10/27/2025 10/27/2025
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Circadian Technologies Limited
CKDXY
CYV
OPT
Opthea US Inc.
Vegenics Pty Ltd.

General Information
Number of Employees: 5 (As of 6/30/2005)
Outstanding Shares: 1,367,978,173 (As of 12/31/2025)
Shareholders: 8,660
Stock Exchange: ASX
Fax Number: +61 398240083


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, July 20, 2026